Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium (68Ga) oxodotreotide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Gallium (68Ga) oxodotreotide (brand name Netspot) is a radioactive diagnostic agent used in positron emission tomography (PET) imaging for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in both adult and pediatric patients. It consists of the somatostatin analog peptide dotatate (DOTA-octreotate) labeled with the positron-emitting radionuclide gallium-68 (Ga-68). Gallium (68Ga) oxodotreotide binds with high affinity to somatostatin receptors, particularly somatostatin receptor subtype 2 (SSTR2), which are overexpressed on the surface of neuroendocrine tumor cells. Upon binding, the positron emissions from the decaying gallium-68 isotope are detected by PET imaging, allowing for high-resolution localization of primary tumors and metastatic lesions. Originally developed by Advanced Accelerator Applications (a Novartis company), it was approved by the FDA in 2016.
- Brand names
- NetspotNetvision
- Other names
- 68Ga-DOTA-TATE68Ga-DOTATATEGa68-DOTATATEGa-68-DOTATATEGa 68-DOTATATEgallium Ga 68 dotatategallium Ga 68 oxodotreotidegallium-68 dotatategallium68 dotatategallium 68 dotatate
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on gallium (68Ga) oxodotreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium (68Ga) oxodotreotide.